Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
AssigneeMERZ PHARMA GmbH & CO. KGaA
InventorHans-Joerg Moebius
Life of this patent
Estimating the term…
Abstract
The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.
Claims13
A method for treating a condition selected from vascular dementia and Alzheimer's disease comprising administering to a patient in need of such treatment a first amount of an 1-aminocyclohexane derivative selected from memantine and salts thereof and a second amount of an acetylcholinesterase inhibitor (AChEI) selected from galantamine, tacrine, donepezil, rivastigmine, huperzine A, zanapezil, ganstigmine, phenserine, phenethylnorcymserine (PENC), cymserine, thiacymserine, SPH 1371 (galantamine plus), ER 127528, RS 1259, and F3796, said first and second amounts in combination being effective in treating the condition.
A method for treating Alzheimer's disease (AD), comprising administering to a patient in need of such treatment a first amount of an 1-aminocyclohexane derivative selected from memantine and salts thereof and a second amount of an acetylcholinesterase inhibitor (AChEI) selected from galantamine, tacrine, donepezil, rivastigmine, huperzine A, zanapezil, ganstigmine, phenserine, phenethylnorcymserine (PENC), cymserine, thiacymserine, SPH 1371 (galantamine plus), ER 127528, RS 1259, and F3796, said first and second amounts in combination being effective at improving at least one of the assessments selected from the group consisting of Severe Impairment Battery (SIB) Test, AD Cooperative Study-Activities of Daily Living (ADCS-ADL) Inventory and Clinician's Interview-Based Impression of Change Plus Version (CIBIC-plus).
A pharmaceutical composition comprising (i) an 1-aminocyclohexane derivative selected from memantine and salts thereof, (ii) an acetylcholinesterase inhibitor (AChEI) selected from galantamine, tacrine, donepezil, rivastigmine, huperzine A, zanapezil, ganstigmine, phenserine, phenethylnorcymserine (PENC), cymserine, thiacymserine, SPH 1371 (galantamine plus), ER 127528, RS 1259, and F3796, and, optionally, (iii) a pharmaceutically acceptable carrier or excipient, wherein the 1-aminocyclohexane derivative and acetylcholinesterase inhibitor (AChEI) are present at therapeutically effective dosages.
Dependencies are inferred from the claim text.